Form 4: Core Scientific Director Jordan Levy Reports Acquisition of Restricted Stock Units

Director Jordan Levy reports acquisition of restricted stock units in Core Scientific, Inc.

Summary

• Jordan Levy, a director of Core Scientific, Inc., reported the acquisition of 127,446 restricted stock units (RSUs) on May 27, 2024.
• These RSUs were granted at a price of $0.
• Levy also acquired an additional 47,793 RSUs on the same date, also at a price of $0.
• Following these transactions, Levy beneficially owns a total of 175,239 shares of common stock.
• The first RSU grant of 127,446 will vest in full on January 23, 2027, provided Levy continues to serve as a non-employee director.
• The second RSU grant of 47,793 will vest in full on January 23, 2025, provided Levy continues to serve as a non-employee director.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider transactions, which doesn't inherently suggest positive or negative implications for the company's performance.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future.
• The vesting schedules incentivize the director to remain with the company.

Future Outlook

The vesting of the RSUs is contingent upon the director's continued service to the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership structure and alignment of interests between management and shareholders.

Stakeholder Impact

• Shareholders may view the RSU grants as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the leadership.

Key Dates